Toripalimab NDA Under Review in Hong Kong for Nasopharyngeal Carcinoma
A new drug application seeking the approval of toripalimab for the treatment of patients with nasopharyngeal carcinoma is under review in Hong Kong.
A new drug application seeking the approval of toripalimab for the treatment of patients with nasopharyngeal carcinoma is under review in Hong Kong.
The USPSTF recommends that women aged 40 to 74 years undergo breast cancer screening mammography every other year. This recommendation applies to anyone assigned female…
For cancer prevention, MD Anderson dietitians recommend eating 18 ounces or fewer of red meat each week. But why is this? We spoke to Research…
Overview The 12th Annual Symposium on Global Cancer Research (ASGCR) will be held virtually May 6 – May 9, 2024 [8AM-12PM Eastern Time each day]. See…
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Alex Spira, MD, PhD, discusses a subset analysis of the phase 3 MARIPOSA trial looking at dose interruptions during the course of amivantamab and lazertinib…
This Viewpoint discusses the ethics of artificial intelligence–generated compassion in cancer care and outlines 4 main points of concern.
Concurrent radical cystectomy and extended lymph node dissection did not show benefit vs standard lymph node dissection in muscle invasive urothelial cancer.
Apalutamide and ADT elicited a 100% biochemical recurrence-free survival rate at 24 months in high-risk localized prostate cancer following radical prostatectomy.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Treatment with TAR-200 displayed a high complete response rate in Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer.